Stock Research: Collegium Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Collegium Pharmaceutical

NasdaqGS:COLL US19459J1043
30
  • Value
    56
  • Growth
    37
  • Safety
    Safety
    21
  • Combined
    14
  • Sentiment
    63
  • 360° View
    360° View
    30
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on products for ADHD and moderate to severe pain. It operates in the biopharmaceutical industry, with commercial products including Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR, and Symproic, primarily in the United States. In the last fiscal year, the company had a market cap of $1,030 million, profits of $377 million, revenue of $631 million, and 357 employees.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
56 63 37 77
Growth
37 65 63 43
Safety
Safety
21 18 25 40
Sentiment
63 82 89 39
360° View
360° View
30 62 56 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
67 75 58 1
Opinions Change
50 50 50 50
Pro Holdings
n/a 88 85 100
Market Pulse
52 51 75 38
Sentiment
63 82 89 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
56 63 37 77
Growth
37 65 63 43
Safety Safety
21 18 25 40
Combined
14 35 22 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
94 96 71 100
Price vs. Earnings (P/E)
61 66 58 66
Price vs. Book (P/B)
19 23 6 44
Dividend Yield
1 1 1 1
Value
56 63 37 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
32 70 27 23
Profit Growth
53 100 100 98
Capital Growth
5 14 18 35
Stock Returns
84 45 77 49
Growth
37 65 63 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
11 12 15 36
Refinancing
37 10 27 31
Liquidity
62 61 59 71
Safety Safety
21 18 25 40

Similar Stocks

Discover high‑ranked alternatives to Collegium Pharmaceutical and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: